Skip to main content

Table 3 Mean percent blood glucose reduction in normal rabbits (N = 6)

From: Influence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal models

Time

(h)

Gliclazide

Efavirenz

Efavirenz + Gliclazide (Single dose treatment)

Efavirenz + Gliclazide (Multiple dose treatment)

1

18.30 ± 1.88

-04.36 ± 1.49

09.25 ± 1.37***

11.54 ± 1.24***

2

24.50 ± 1.24

-06.16 ± 1.93

14.96 ± 1.12***

16.61 ± 1.21***

3

34.25 ± 0.99

-03.63 ± 1.24

24.97 ± 0.87***

27.14 ± 0.67***

4

25.92 ± 1.30

-01.48 ± 1.22

14.61 ± 1.22***

16.97 ± 1.40***

6

24.50 ± 0.96

-00.04 ± 0.98

12.44 ± 1.59***

14.05 ± 1.53***

8

18.96 ± 2.85

02.09 ± 1.94

10.69 ± 0.70***

12.28 ± 0.80**

12

10.39 ± 1.32

04.22 ± 2.31

08.89 ± 1.23

10.78 ± 1.86

16

05.71 ± 1.13

06.03 ± 1.87

04.59 ± 1.35

06.51 ± 0.54

20

04.24 ± 1.54

05.31 ± 2.28

03.17 ± 1.29

03.87 ± 2.26

24

02.08 ± 1.47

04.60 ± 1.78

01.42 ± 0.45

02.85 ± 0.90

  1. ***Significant at P < 0.001 compared to gliclazide control
  2. **Significant at P < 0.01 compared to gliclazide control